Addex Therapeutics Receivables

As of the most recent data (March 2026), ADXN shows a receivables of $32K. That compares with $35K in the prior-year period — down 9.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ADXN's receivables is now $32K (was $35K) — a 9.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Addex Therapeutics is outperforming or lagging.

Tracking ADXN's receivables over time shows whether Addex Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $32K That compares with $35K in the prior-year period — down 9.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Addex Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $32K) with ownership activity and broader fundamentals.

Addex Therapeutics's receivables is $32K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.